Three clinical studies were conducted about losing weight with a medicinal drug.
However, this medicinal drug was not a pill. It is a medicinal drug that must be subcutaneously injected.
This medicinal drug was semaglutide. It belongs the class of GLP-1 receptor agonists.
All three clinical studies were successful.
Overweight or obese participants lost more weight with the subcutaneous medicinal drug, compared with the subcutaneous placebo.
In all three clinical studies, the participants with the medicinal drug had more gastrointestinal side effects, compared with the participants with the placebo.
One concern of note is the short follow-up of these clinical studies.
To address this concern, the manufacturer is conducting a new clinical study, which will have a long follow-up.